Recent News

• 12.01.2025 - LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
• 11.25.2025 - LENZ Therapeutics to Present at Upcoming Investor Conferences
• 11.05.2025 - LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
• 10.29.2025 - LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025
• 09.30.2025 - LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

Recent Filings

• 11.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.17.2025 - 144 Report of proposed sale of securities
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.10.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 11.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.07.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 11.07.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.05.2025 - EX-99.1 EX-99.1